South Africa is in discussions with Gilead Sciences (GILD) to reach an agreement that allows the production of the U.S. biotech’s new twice-yearly HIV therapy, lenacapavir, in the country, home to the ...
South Africa’s National Aids Council, Sanac, has asked local drug companies to submit applications by April 7 to make generic ...
AllAfrica on MSN
Bringing it home - South Africa is leading the charge to make anti-HIV jab for Africa
South Africa's National Aids Council, Sanac, has asked local drug companies to submit applications by April 7 to make generic versions of an anti-HIV jab that could end Aids by 2043 in the country.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results